TD Cowen Issues Positive Forecast for Teva Pharmaceutical Industries (NYSE:TEVA) Stock Price

Teva Pharmaceutical Industries (NYSE:TEVA) had its price objective boosted by research analysts at TD Cowen from $55.00 to $57.00 in a research note issued to investors on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the stock. TD Cowen‘s target price indicates a potential upside of 35.72% from the stock’s previous close.

TEVA has been the subject of a number of other research reports. Oppenheimer boosted their price target on Teva Pharmaceutical Industries from $50.00 to $52.00 and gave the company an “outperform” rating in a report on Friday, October 9th. Wall Street Zen downgraded Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. JPMorgan Chase & Co. lifted their target price on Teva Pharmaceutical Industries from $40.00 to $50.00 and gave the company an “overweight” rating in a research report on Monday, October 12th. Weiss Ratings upgraded Teva Pharmaceutical Industries from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, October 8th. Finally, Zacks Research downgraded Teva Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 20th. Thirteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and a consensus target price of $46.69.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA stock traded up $0.09 on Wednesday, reaching $42.00. The stock had a trading volume of 5,660,564 shares, compared to its average volume of 6,797,240. The stock has a market cap of $48.94 billion, a P/E ratio of 69.79, a price-to-earnings-growth ratio of 3.77 and a beta of 0.97. The company has a debt-to-equity ratio of 1.56, a quick ratio of 0.67 and a current ratio of 0.88. Teva Pharmaceutical Industries has a 1 year low of $22.70 and a 1 year high of $43.34. The company has a 50 day simple moving average of $39.24 and a 200 day simple moving average of $34.64.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Tuesday, November 3rd. The company reported $0.86 EPS for the quarter, topping the consensus estimate of $0.72 by $0.14. Teva Pharmaceutical Industries had a net margin of 4.08% and a return on equity of 32.64%. The firm had revenue of $4.39 billion for the quarter, compared to the consensus estimate of $4.23 billion. During the same quarter in the previous year, the firm earned $0.78 earnings per share. The company’s quarterly revenue was down 1.9% compared to the same quarter last year. Equities research analysts expect that Teva Pharmaceutical Industries will post 2.00 EPS for the current year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Brian Savage sold 7,342 shares of the business’s stock in a transaction that occurred on Friday, September 18th. The stock was sold at an average price of $38.85, for a total value of $285,236.70. Following the sale, the insider owned 8,500 shares of the company’s stock, valued at $330,225. The trade was a 46.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Roberto Mignone sold 367,600 shares of the firm’s stock in a transaction that occurred on Friday, September 18th. The shares were sold at an average price of $39.06, for a total transaction of $14,358,456.00. Additional details regarding this sale are available in the official SEC disclosure. 0.54% of the stock is currently owned by corporate insiders.

Institutional Trading of Teva Pharmaceutical Industries

Several institutional investors and hedge funds have recently bought and sold shares of TEVA. Cornerstone Planning Group LLC raised its position in Teva Pharmaceutical Industries by 547.1% in the first quarter. Cornerstone Planning Group LLC now owns 893 shares of the company’s stock worth $27,000 after acquiring an additional 755 shares in the last quarter. Root Financial Partners LLC purchased a new position in Teva Pharmaceutical Industries during the third quarter worth $33,000. Western Wealth Management LLC acquired a new position in shares of Teva Pharmaceutical Industries in the first quarter valued at approximately $43,000. Sunbelt Securities Inc. purchased a new position in Teva Pharmaceutical Industries during the first quarter worth about $45,000. Finally, EverSource Wealth Advisors LLC grew its stake in shares of Teva Pharmaceutical Industries by 64.0% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,658 shares of the company’s stock valued at $50,000 after buying an additional 647 shares during the period. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Key Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Teva reported Q3 adjusted EPS of $0.86, above the $0.72 analyst consensus, and revenue of about $4.39 billion, topping estimates of $4.23 billion. The earnings beat and stronger branded-drug sales helped prompt higher 2026 revenue and product-sales guidance. Teva Q3 earnings beat and guidance raised
• Positive Sentiment: UZEDY, Teva’s long-acting schizophrenia treatment, generated $85 million in U.S. Q3 sales, up 96% year over year. Teva raised its 2026 UZEDY revenue outlook to $290–$310 million from $270–$290 million, providing evidence of momentum in its growth portfolio. UZEDY sales and outlook
• Positive Sentiment: A deal with Samsung Bioepis gives Teva U.S. commercialization rights to two FDA-approved biosimilars, expanding its immunology portfolio and potentially adding future revenue. Teva and Samsung Bioepis agreement
• Positive Sentiment: Management expects growth to accelerate in 2027 despite U.S. Inflation Reduction Act pressure on Austedo, suggesting confidence in the broader business and newer products. Teva outlook for 2027
• Negative Sentiment: Q3 revenue was down 1.9% year over year, reflecting pressure including generic-drug declines. Teva also ended its Phase 2 TOPAS-MSA study of emrusolmin after an interim analysis indicated a low likelihood of meeting the efficacy target. The decision removes a potential pipeline opportunity, although no safety concerns were identified. Teva discontinues emrusolmin trial

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. Founded in 1901, the company is one of the world’s largest producers of generic medicines and develops, manufactures and distributes prescription products across a broad range of therapeutic areas.

Teva’s portfolio includes generic medicines, specialty pharmaceuticals, biosimilars, active pharmaceutical ingredients and over-the-counter products. Its specialty medicines include treatments for neurological and movement disorders, respiratory conditions, migraine and other chronic diseases.